Form 4: Allogene GC Sells Shares for Tax, Receives New Equity

Allogene Therapeutics' SVP, General Counsel, Douglas Earl Martin, sold shares to cover tax obligations while simultaneously receiving new stock option and restricted stock unit awards.

Summary

• Douglas Earl Martin, SVP, General Counsel of Allogene Therapeutics, Inc. (ALLO), reported transactions on February 2, 2026.
• Martin sold 22,900 shares of Common Stock at a weighted average price of $1.76 per share (ranging from $1.71 to $1.82).
• This sale was non-discretionary, mandated by the Issuer's equity incentive plan to cover tax withholding obligations related to the vesting of restricted stock units.
• Following the sale, Martin beneficially owns 564,948 shares of Common Stock.
• Martin was granted 539,072 stock options with an exercise price of $1.87 per share, vesting 25% on February 2, 2027, and the remainder in 36 equal monthly installments thereafter, expiring on February 2, 2036.
• Martin also received an award of 152,480 Restricted Stock Units (RSUs), which will vest in 4 successive equal annual installments from February 2, 2026, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While there was a share sale, it was non-discretionary for tax purposes. The significant new equity grants (stock options and RSUs) represent a positive alignment of executive incentives with future company performance.

Positives

• The reporting person received a significant grant of 539,072 stock options, aligning management's interests with long-term share price appreciation.
• An award of 152,480 Restricted Stock Units (RSUs) further incentivizes continued service and performance.

Negatives

• The reporting person sold 22,900 shares of Common Stock, reducing their direct beneficial ownership, although this was a non-discretionary 'sell to cover' transaction for tax purposes.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the combination of a 'sell to cover' transaction for tax obligations and new equity grants (stock options and RSUs) is a common occurrence for executives in publicly traded companies, particularly in the biotechnology sector. This reflects standard compensation practices designed to align executive incentives with long-term shareholder value while managing tax liabilities associated with equity vesting.

Comparison to Industry Standards

• Equity compensation, including stock options and Restricted Stock Units (RSUs), is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize executive talent. Companies such as Gilead Sciences, Amgen, and Regeneron Pharmaceuticals frequently utilize similar equity-based incentive structures for their senior management.
• The 'sell to cover' mechanism for tax withholding is also a widely adopted practice, ensuring compliance with tax obligations upon the vesting of equity awards without requiring executives to use personal funds or make discretionary sales that could be misinterpreted by the market.
• The vesting schedules (e.g., 4-year annual installments for RSUs, 25% after one year then monthly for options) are typical for executive compensation, designed to promote long-term commitment and performance.

Stakeholder Impact

• Shareholders gain insight into executive compensation and routine insider trading activity, which generally indicates ongoing executive commitment through new equity grants.
• Employees (specifically the reporting person) benefit from continued equity-based compensation, aligning their financial interests with the company's long-term success.

Next Steps

• The granted stock options will begin vesting with 25% on February 2, 2027, followed by 36 equal monthly installments.
• The Restricted Stock Units will vest in 4 successive equal annual installments starting from February 2, 2026, contingent on continued service.

Key Dates

Keywords

Allogene Therapeutics, ALLO, Form 4, Insider Transaction, Stock Option, Restricted Stock Unit, Equity Compensation, General Counsel, Sell to Cover